A Single Arm, Open-Label Phase I Study to Evaluate the Safety and Tolerability of ISC-hpNSC Injected Into the Striatum and Substantia Nigra of Patients With Parkinson's Disease

Trial Profile

A Single Arm, Open-Label Phase I Study to Evaluate the Safety and Tolerability of ISC-hpNSC Injected Into the Striatum and Substantia Nigra of Patients With Parkinson's Disease

Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Apr 2018

At a glance

  • Drugs ISC-hpNSC (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; First in man
  • Sponsors Cyto Therapeutics
  • Most Recent Events

    • 10 Apr 2018 According to an International Stem Cell Corporation media release, positive interim results of this trial were presented at the Society for Neuroscience Annual Meeting (Neuroscience 2017).
    • 10 Apr 2018 According to an International Stem Cell Corporation media release, positive interim results of this trial were presented at the American Society of Gene and Cell Therapy 20th Annual Meeting (2017).
    • 10 Apr 2018 According to an International Stem Cell Corporation media release, positive interim results of this trial were presented at the American Society for Neural Therapy and Repair Annual Meeting (2017).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top